Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B

Hepatology International

Volumn 7, Issue 4, 2013, Pages 981-989

  Al Mahtab, Mamun ^a   Akbar, Sheikh Mohammad Fazle ^b   Aguilar, Julio Cesar ^c   Uddin, Md Helal ^d   Khan, Md Sakirul Islam ^e   Rahman, Salimur ^a  

^a BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

^b Shinagawa ku   (Japan)

^c CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^d Clinical Research Organization   (Bangladesh)

^e BANGLADESH AGRICULTURAL UNIVERSITY   (Bangladesh)

Author keywords

Chronic hepatitis B; HBsAg HBcAg vaccine; Immunotherapy; Therapeutic vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INDIGESTION; INJECTION SITE PAIN; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; YOUNG ADULT;

EID: 84890560399     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-013-9486-4     Document Type: Article

References (30)

1. Zoulim F, Perrillo R, Hepatitis B. Reflections on the current approach to antiviral therapy. J Hepatol. 2008;48(Suppl 1):S2-19
2. Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother. 2011;12:2025-2040
3. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34:593-602
4. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971-975
5. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-1531
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-807
7. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437-1444
8. Wilt TJ, Shamliyan T, Shaukat A, Taylor BC, MacDonald R, Yuan JM, et al. Management of chronic hepatitis B. Evid Rep Technol Assess (Full Rep). 2008;174:1-671
9. Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med. 2009;150:111-124
10. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:29-60
11. Rehermann B. Immune responses to hepatitis B virus infection. Semin Liver Dis. 2003;23:21-37
12. Sprengers D, Janssen HL. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol. 2005;19:17-26
13. Pol S, Driss F, Michel ML, Nalpas B, Berthelot P, Brechot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet. 1994;344:342
14. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol. 2001;34:917-921
15. Vandepapelière P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, et al. Vaccine Group of Investigators. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine. 2007;25:8585-8597
16. Akbar SM, Furukawa S, Horiike N, Abe M, Hiasa Y, Onji M. Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B. J Viral Hepat. 2010;18:408-414
17. Luo J, Li J, Chen RL, Nie L, Huang J, Liu ZW, et al. Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. Vaccine. 2010;28:2497-2504
18. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000;191:1269-1280
19. Lau GK, Lok AS, Liang RH, Lai CL, Chiu EK, Lau YL, et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology. 1997;25:1497-1501
20. Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillén G, Aguilar JC. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol. 2005;42:289-294
21. Akbar SM, Yoshida O, Chen S, Aguilar AJ, Abe M, Matsuura B, et al. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection. Antivir Ther. 2010;15:887-895
22. Betancourt AA, Delgado CA, Estévez ZC, Martínez JC, Ríos GV, Aureoles-Roselló SR, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis. 2007;11:394-401
23. Aguilar JC, Lobaina Y, Muzio V, García D, Pentón E, Iglesias E, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol. 2004;82:539-546
24. Al-Mahtab M, Rahman S, Akbar SM, Kamal M, Khan SI. Clinical use of liver biopsy for the diagnosis and management of inactive and asymptomatic hepatitis B virus carriers in Bangladesh. J Med Virol. 2010;82:1350-1354
25. Akbar SM, Furukawa S, Yoshida O, Hiasa Y, Horiike N, Onji M. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J Hepatol. 2007;47:60-66
26. Miyake T, Akbar SM, Yoshida O, Chen S, Hiasa Y, Matsuura B, et al. Impaired dendritic cell functions disrupt antigen-specific adaptive immune responses in mice with nonalcoholic fatty liver disease. J Gastroenterol. 2010;45:859-867
27. Akbar SM, Horiike N, Chen S, Michitaka K, Abe M, Hiasa Y, et al. Mechanism of restoration of immune responses of chronic hepatitis B patients during lamivudine therapy; increased antigen processing and presentation by dendritic cells. J Viral Hepat. 2011;18:200-205
28. Akbar SM, Chen S, Al-Mahtab M, Abe M, Hiasa Y, Onji M. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antiviral Res. 2012;96:59-64
29. Davis SS. Nasal vaccines. Adv Drug Deliv Rev. 2001;51:21-42
30. Eriksson K, Kilander A, Hagberg L, Norkrans G, Holmgren J, Czerkinsky C. Intestinal antibody responses to oral vaccination in HIV-infected individuals. AIDS. 1993;7:1087-1091